To evaluate whether EFR3A was similarly required for KRAS-mutant pancreatic tumor growth, the aforementioned HPAF-II cells, in which the expression of EFR3A, EFR3B, or both genes was verified to be reduced (Fig. 3f), were injected subcutaneously into immunocompromised mice. The gene discussed is KRAS; the disease is pancreatic neoplasm.